Efficiency of Azithromycin-Loaded Lipid Polymer Hybrid Nano-vehicle as a Repurposing formulation in Colon Cancer Management

Colorectal cancer (CRC) despite notable progress in treatment still ranks third in terms of occurrences and second in terms of mortality. Numerous synthetic chemotherapies have been used in CRC; nevertheless, they do not specifically target cancerous cells resulting in serious side effects and signi...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلف الرئيسي: Tarraf, Vanessa (author)
التنسيق: masterThesis
منشور في: 2025
الوصول للمادة أونلاين:http://hdl.handle.net/10725/17115
https://doi.org/10.26756/th.2023.821
http://libraries.lau.edu.lb/research/laur/terms-of-use/thesis.php
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
_version_ 1864513473998749696
author Tarraf, Vanessa
author_facet Tarraf, Vanessa
author_role author
dc.creator.none.fl_str_mv Tarraf, Vanessa
dc.date.none.fl_str_mv 2025-07-14T06:19:12Z
2025-07-14T06:19:12Z
2025
2025-05-12
dc.identifier.none.fl_str_mv http://hdl.handle.net/10725/17115
https://doi.org/10.26756/th.2023.821
http://libraries.lau.edu.lb/research/laur/terms-of-use/thesis.php
dc.language.none.fl_str_mv en
dc.publisher.none.fl_str_mv Lebanese American University
dc.rights.*.fl_str_mv info:eu-repo/semantics/openAccess
dc.title.none.fl_str_mv Efficiency of Azithromycin-Loaded Lipid Polymer Hybrid Nano-vehicle as a Repurposing formulation in Colon Cancer Management
dc.type.none.fl_str_mv Thesis
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/masterThesis
description Colorectal cancer (CRC) despite notable progress in treatment still ranks third in terms of occurrences and second in terms of mortality. Numerous synthetic chemotherapies have been used in CRC; nevertheless, they do not specifically target cancerous cells resulting in serious side effects and significant harm to healthy cells. Accordingly, many alternative safer therapies have been extensively investigated against CRC. Azithromycin (AZI), a member of macrolides antibiotics, has been reported to inhibit the proliferation of cancer cells by targeting mitochondria and eradicating cancer cells. Despite its promising therapeutic activity, it is restricted by its poor aqueous solubility leading to efforts focusing on the development of safe and efficient anticancer Nano carriers. Liposomes are the most widely studied Nano-drug carriers in drug delivery. Compared with other Nano carriers, liposomes exhibit prominent properties that include targeted delivery, high biocompatibility, biodegradability, low toxicity, and improved therapeutic indices. Thus, the current work aims is to design a liposome to augment azithromycin anticancer effects. Liposome was prepared from soybean phospholipid using an ethanol injection technique and coated chitosan. The designed coated and uncoated systems were characterized both physicochemically and on colorectal cancer cell line in vitro. The results displayed Nano metric size range for azithromycin-loaded uncoated and coated liposomes of values 65.5± 2.83 nm and 73.53 ± 2.01 nm, respectively with uni-modal particle size distribution with PDI less than 0.3. The shifting of the negative charge (-17.22± 5.99 mV) of the uncoated liposomes to the positive charge (13.17± 3.34 mV) of the coated one approved the success of the coating. The formulation showed ideal characteristics of 70% AZI entrapment and in vitro controlled release. It displayed a safe profile on HT29 cell line, with the coated formulation having the lowest IC50= 24.17 μM at 24 hours that even decreases at longer time intervals, which confirms its potential for colorectal cancer management.
eu_rights_str_mv openAccess
format masterThesis
id LAURepo_926fe8e9b570d50cb6aff2069b8dff70
language_invalid_str_mv en
network_acronym_str LAURepo
network_name_str Lebanese American University repository
oai_identifier_str oai:laur.lau.edu.lb:10725/17115
publishDate 2025
publisher.none.fl_str_mv Lebanese American University
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
spelling Efficiency of Azithromycin-Loaded Lipid Polymer Hybrid Nano-vehicle as a Repurposing formulation in Colon Cancer ManagementTarraf, VanessaColorectal cancer (CRC) despite notable progress in treatment still ranks third in terms of occurrences and second in terms of mortality. Numerous synthetic chemotherapies have been used in CRC; nevertheless, they do not specifically target cancerous cells resulting in serious side effects and significant harm to healthy cells. Accordingly, many alternative safer therapies have been extensively investigated against CRC. Azithromycin (AZI), a member of macrolides antibiotics, has been reported to inhibit the proliferation of cancer cells by targeting mitochondria and eradicating cancer cells. Despite its promising therapeutic activity, it is restricted by its poor aqueous solubility leading to efforts focusing on the development of safe and efficient anticancer Nano carriers. Liposomes are the most widely studied Nano-drug carriers in drug delivery. Compared with other Nano carriers, liposomes exhibit prominent properties that include targeted delivery, high biocompatibility, biodegradability, low toxicity, and improved therapeutic indices. Thus, the current work aims is to design a liposome to augment azithromycin anticancer effects. Liposome was prepared from soybean phospholipid using an ethanol injection technique and coated chitosan. The designed coated and uncoated systems were characterized both physicochemically and on colorectal cancer cell line in vitro. The results displayed Nano metric size range for azithromycin-loaded uncoated and coated liposomes of values 65.5± 2.83 nm and 73.53 ± 2.01 nm, respectively with uni-modal particle size distribution with PDI less than 0.3. The shifting of the negative charge (-17.22± 5.99 mV) of the uncoated liposomes to the positive charge (13.17± 3.34 mV) of the coated one approved the success of the coating. The formulation showed ideal characteristics of 70% AZI entrapment and in vitro controlled release. It displayed a safe profile on HT29 cell line, with the coated formulation having the lowest IC50= 24.17 μM at 24 hours that even decreases at longer time intervals, which confirms its potential for colorectal cancer management.Lebanese American University2025-07-14T06:19:12Z2025-07-14T06:19:12Z20252025-05-12Thesisinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesishttp://hdl.handle.net/10725/17115https://doi.org/10.26756/th.2023.821http://libraries.lau.edu.lb/research/laur/terms-of-use/thesis.phpeninfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/171152025-07-14T07:22:00Z
spellingShingle Efficiency of Azithromycin-Loaded Lipid Polymer Hybrid Nano-vehicle as a Repurposing formulation in Colon Cancer Management
Tarraf, Vanessa
status_str publishedVersion
title Efficiency of Azithromycin-Loaded Lipid Polymer Hybrid Nano-vehicle as a Repurposing formulation in Colon Cancer Management
title_full Efficiency of Azithromycin-Loaded Lipid Polymer Hybrid Nano-vehicle as a Repurposing formulation in Colon Cancer Management
title_fullStr Efficiency of Azithromycin-Loaded Lipid Polymer Hybrid Nano-vehicle as a Repurposing formulation in Colon Cancer Management
title_full_unstemmed Efficiency of Azithromycin-Loaded Lipid Polymer Hybrid Nano-vehicle as a Repurposing formulation in Colon Cancer Management
title_short Efficiency of Azithromycin-Loaded Lipid Polymer Hybrid Nano-vehicle as a Repurposing formulation in Colon Cancer Management
title_sort Efficiency of Azithromycin-Loaded Lipid Polymer Hybrid Nano-vehicle as a Repurposing formulation in Colon Cancer Management
url http://hdl.handle.net/10725/17115
https://doi.org/10.26756/th.2023.821
http://libraries.lau.edu.lb/research/laur/terms-of-use/thesis.php